Filing Flows › Evofem Biosciences (EVFM) › Q2 2025
Evofem Biosciences (EVFM) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
Evofem Biosciences (EVFM) reported revenue of $4.8M for the second quarter 2025 (Q2 2025), +16% from a year earlier and +471% from the quarter before. Operating margin was -25.9%, net loss $1.8M (37.0% of revenue).
Evofem Biosciences, Q2 2025: revenue $4.8M (+16% year over year), operating margin -25.9%, net loss $1.8M, operating cash flow −$2.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4.8M | +471% | +16% |
| Operating profit | −$1.3M | -483% | — |
| Net earnings | −$1.8M | -287% | — |
| Operating cash flow | −$2.9M | -621% | — |
What changed
Revenue was $4.8M in Q2 2025, up 16% year over year and up 471% from the previous quarter.
Operating costs exceeded revenue by $1.3M, an operating margin of -25.9%. Total costs grew 9% against revenue growth of 16%. The fastest-growing cost line was Sales & marketing (+17%). The quarter ended with a net loss of $1.8M, after a profit of $1.0M the previous quarter.
Operating cash flow was −$2.9M. Non-cash charges added back $111K of depreciation and amortization and $31K of share-based compensation. Working capital and other items used $1.3M.
Questions
What was Evofem Biosciences' revenue in the second quarter 2025?
Evofem Biosciences (EVFM) reported revenue of $4.8M for the second quarter 2025 (Q2 2025), +16% from a year earlier and +471% from the quarter before.
Was Evofem Biosciences profitable in the second quarter 2025?
Operating loss was $1.3M (-25.9% of revenue) and net loss $1.8M.
Source: Evofem Biosciences 10-Q on SEC EDGAR.